Neil Frankish obtained his Ph.D. in pharmacology from the university of Strathclyde, UK. A period of post doctoral research at Leeds University, UK, on the development of the calcium channel blocker bepridil (Vascor) focused his interest on novel drug development. With Assoc. Prof. Helen Sheridan, he is a co-founder of Trino Therapeutics, a commercial spin-out company from the School of Pharmacy. His recent research focus has been on Trino Therapeutics’ proprietary class of drugs made of novel indane dimer derivatives. He has characterised these potential drug candidates in several disease models in the areas of allergy and inflammation and explored their possible applications in a broad range of therapeutic areas. He is a co-inventor of Trino’s key drug class patents and together with Assoc. Prof. Sheridan has been responsible for taking a New Chemical Entity (NCE) from the drawing board through to human subjects.
The Wellcome Trust, Fountain Healthcare, Enterprise Ireland, Unimed PLC .